IRCT20230801058996N4Not yet recruitingPhase 1
Safety and efficacy of modified donor lymphocyte infusion (DLI) in reducing infection risk in adult patients with acute leukemia following allogeneic hematopoietic stem cell transplantation
Trial Snapshot
- Phase
- Phase 1
- Status
- Not yet recruiting
- Enrollment
- 12
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20 years to 70 years (—)
- Sex
- All
Inclusion Criteria
- •Transplantation of T cell replete haplotype with cyclophosphamide
- •The estimated life expectancy more than one year
- •Karnofsky index above 70%
Exclusion Criteria
- •GVHD of grade 2 or less
- •Uncontrolled bacterial infection
- •Insufficient intake: WBC<2500/mm3 and Platelet<50000/mm3
- •Evidence of recurrence
- •Concomitant treatment with corticosteroids and/or other immunosuppressive drugs
- •Infection with hepatitis B, C and HIV pathogens
Investigators
Similar Trials
Terminated
Phase 2
Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical DonorMyeloid LeukemiaLymphoblastic LeukemiaMyeloproliferative DisordersMultiple MyelomaLymphomaMyelodysplastic SyndromeNCT00967343Kiadis Pharma40
Completed
Phase 1
Adoptive transfer of lymphocytes transduced with MAGE-A4-specific TCR gene for therapy-resistant esophageal cancerJPRN-UMIN000002395Mie University Hospital9
Completed
Phase 1
Adoptive transfer of lymphocytes transduced with MAGE-A4-specific TCR gene following lymphodepleting conditioning for therapy-resistant esophageal cancerTherapy-resistant esophageal cancerJPRN-UMIN000010729Department of Immuno-gene Therapy, Mie University Graduate School of Medicine12
Completed
Not Applicable
Feasibility and Efficacy of Modified Donor Lymphocytes Infusion (CD45RA Negative Selected) After Haploidentical Transplantation With Post-transplantation Cyclophosphamide in Patients With Hematological Malignancies (ONC-2016-002).Bone Marrow Transplant InfectionBone Marrow Transplant ComplicationsGraft Vs Host DiseaseInfectionHematological MalignancyNCT04687982Istituto Clinico Humanitas19
Terminated
Phase 1
Donor Lymphocyte Infusion After Alternative Donor TransplantationImmunodeficiencyNCT01027702Wake Forest University Health Sciences38